Related Experiment Video
Updated: Jul 13, 2026

Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
Possible involvement of post-dopamine D2 receptor signalling components in the pathophysiology of schizophrenia
Shirly Amar1, Galit Shaltiel, Liad Mann
1Stanley Research Center, Faculty of Health Science, Ben-Gurion University of the Negev, and Mental Health Center, Beer-Sheva, Israel.
Abstract:
Par-4 has been suggested to mediate dopamine neurotransmission. Dopamine D2 receptor (DRD2) activation induces a signalling complex of AKT1, PP2A and beta-arrestin2 which dephosphorylates/inactivates AKT1 thereby activating GSK-3beta, transducing dopamine-dependent behaviour. DRD2 activation also results in down-regulation of PKA activity. Among other substrates PKA phosphorylates GSK-3beta. Prolonged DRD2 activation leads to its 'desensitization' which involves GRKs and beta-arrestins. beta-arrestin1 binds to phosphorylated receptors preventing further G-protein stimulation. This study examined whether Par-4, beta-arrestin1, AKT1 and GSK-3beta are involved in the pathophysiology of schizophrenia. Lymphocytes obtained from schizophrenia and bipolar patients and healthy controls recruited from the Beer-Sheva Mental Health Center were transformed by Epstein-Barr virus (EBV) into lymphocyte-derived cell lines (LDCL). Post-mortem brain samples were obtained from the Rebecca L. Cooper Brain Bank, Parkville, Australia. The study was approved by the IRB committees of Beer-Sheva, Israel and Parkville, Australia. Levels of the specific proteins were assayed by Western blotting. beta-arrestin1 protein levels were significantly ~2-fold increased in LDCL from schizophrenia patients while Par-4 protein levels were unaltered. A 63% significant decrease was found in frontal cortex phospho-Ser9-GSK-3beta protein levels in schizophrenia but not in those of AKT1, Par-4 or beta-arrestin1. Elevated beta-arrestin1 protein levels in LDCL and decreased phospho-Ser9-GSK-3beta protein levels in post-mortem frontal cortex of schizophrenia patients vs. control groups support the possible involvement of these proteins in the pathophysiology of schizophrenia. However, since we did not find differences in beta-arrestin1, AKT1 and Par-4 protein levels in post-mortem frontal cortex of schizophrenia patients and although GSK-3beta participates in other signalling cascades we can not rule out the possibility that the differences found reflect deviation in DRD2 signalling.
Insights
Schizophrenia may involve elevated beta-arrestin1 and reduced phospho-Ser9-GSK-3beta. These findings in lymphocytes and brain tissue suggest altered dopamine D2 receptor signaling in the disorder.
Area of Science:
- Neuroscience
- Molecular Biology
- Psychiatry
Background:
- Dopamine D2 receptor (DRD2) signaling is crucial for neurotransmission and behavior.
- DRD2 activation involves protein complexes that regulate AKT1 and GSK-3beta activity.
- Schizophrenia pathophysiology may involve disruptions in these signaling pathways.
Purpose of the Study:
- To investigate the role of Par-4, beta-arrestin1, AKT1, and GSK-3beta in schizophrenia.
- To examine protein levels in lymphocyte-derived cell lines (LDCL) and post-mortem brain samples from schizophrenia patients.
Main Methods:
- Western blotting was used to assay protein levels in LDCL and frontal cortex samples.
- Lymphocytes from schizophrenia, bipolar patients, and healthy controls were used to create LDCL.
- Post-mortem brain samples were obtained for analysis.
Main Results:
- Beta-arrestin1 protein levels were significantly increased in LDCL from schizophrenia patients.
- A significant decrease in frontal cortex phospho-Ser9-GSK-3beta protein levels was observed in schizophrenia patients.
- No significant differences were found in AKT1, Par-4, or beta-arrestin1 protein levels in the frontal cortex.
Conclusions:
- Elevated beta-arrestin1 in LDCL and decreased phospho-Ser9-GSK-3beta in the frontal cortex suggest their involvement in schizophrenia pathophysiology.
- The findings support a potential role for altered DRD2 signaling in schizophrenia.
- Further research is needed to fully elucidate the contribution of these proteins to the disorder.
Related Concept Videos
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within the...
Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin studies.
Parkinson Disease ll: Pathophysiology
Psychological and Sociocultural Causes of Schizophrenia
Drugs Affecting Neurotransmitter Synthesis
Antipsychotic Drugs: Typical and Atypical Agents

